BDX vs PMCB · P/E 34, rev $21.84B vs $8.6M cap
Becton Dickinson and Company (BDX) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Becton Dickinson and Company (BDX) is a medical instruments & supplies company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported BDX revenue for 2025-09-30 was $21.84B. Net income was $1.68B. Revenue was up 8.2% from 2024-09-30 to 2025-09-30. BDX currently screens at market cap $50.30B and trailing P/E 33.9.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
BDX currently screens at market cap $50.30B and trailing P/E 33.9. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the BDX and PMCB stock pages for the full models.
Not investment advice.